Clinical Trial Update: Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD [Phase 3]

View source ↗

Summary

This update reports termination of an open-label Phase 3 trial evaluating posterior juxtascleral injections of anecortave acetate 15 mg for long-term use in age…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• anecortave acetate (anecortave acetate)

Snippet

Sponsor: Alcon Research | Conditions: Macular Degeneration | Phase 3 | Status: TERMINATED